Published in J Neurol Neurosurg Psychiatry on February 01, 2006
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist (2012) 1.27
Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet (2007) 1.08
Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics (2012) 1.06
Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res (2012) 1.03
News on the genetics, epidemiology, medical care and translational research of Schwannomas. J Neurol (2006) 0.84
Neurofibromatosis type 2: a case of ptosis. Graefes Arch Clin Exp Ophthalmol (2007) 0.80
Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb. BMC Med Genomics (2015) 0.76
Neurofibromatosis Type 2 Presenting with Oculomotor Ophthalmoplegia and Distal Myopathy. Case Rep Ophthalmol Med (2016) 0.75
Schwannomatosis: a clinical and pathologic study. Neurology (1996) 2.82
Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet (2003) 2.12
Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet (1997) 1.96
Multiple schwannomas: schwannomatosis or neurofibromatosis type 2? J Neurosurg (1998) 1.80
Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry (1997) 1.26
Schwannomatosis. An unusual variant of neurofibromatosis or a distinct clinical entity? Arch Dermatol (1989) 1.16
Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol (1995) 1.12
Multiple cutaneous neurilemmomas as a skin manifestation of neurilemmomatosis. J Am Acad Dermatol (1984) 1.10
Somatic instability of the NF2 gene in schwannomatosis. Arch Neurol (2003) 1.08
Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet (2003) 1.07
Linkage relationship of a cloned DNA sequence on the short arm of the X chromosome to Duchenne muscular dystrophy. Nature (1982) 11.57
Linkage analysis of two cloned DNA sequences flanking the Duchenne muscular dystrophy locus on the short arm of the human X chromosome. Nucleic Acids Res (1983) 8.92
Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature (1992) 8.85
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet (1993) 5.70
Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet (2002) 5.06
Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain (1988) 4.69
A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet (1989) 4.42
Clinical aspects of X-linked hypohidrotic ectodermal dysplasia. Arch Dis Child (1987) 2.95
Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet (1996) 2.88
Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science (1988) 2.82
The prevention of Huntington's chorea. The Milroy lecture 1985. J R Coll Physicians Lond (1986) 2.74
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet (2006) 2.68
Genetic risks for children of women with myotonic dystrophy. Am J Hum Genet (1991) 2.65
The use of linked DNA polymorphisms for genotype prediction in families with Duchenne muscular dystrophy. J Med Genet (1983) 2.45
Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet (1993) 2.42
Early-onset dystrophia myotonica. Evidence supporting a maternal environmental factor. Lancet (1972) 2.40
Unstable DNA sequence in myotonic dystrophy. Lancet (1992) 2.36
Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain (2008) 2.34
Huntington's Chorea in South Wales. A genetic and epidemiological study. Clin Genet (1981) 2.31
An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23
Studies of a DNA marker (G8) genetically linked to Huntington disease in British families. Hum Genet (1986) 2.18
Genetic linkage between Becker muscular dystrophy and a polymorphic DNA sequence on the short arm of the X chromosome. J Med Genet (1983) 2.16
Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet (1993) 2.15
Exclusion testing for Huntington's disease in pregnancy with a closely linked DNA marker. Lancet (1987) 2.09
Adoption and genetic prediction for Huntington's disease. Lancet (1988) 2.09
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
Polycystic kidney disease re-evaluated: a population-based study. Q J Med (1991) 2.05
Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A (2010) 2.05
Linkage disequilibrium in Huntington's disease: an improved localisation for the gene. J Med Genet (1989) 2.05
Congenital myotonic dystrophy in Britain. I. Clinical aspects. Arch Dis Child (1975) 2.04
Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD) Hum Mol Genet (1995) 2.02
Problems in genetic prediction for Huntington's disease. Lancet (1989) 2.00
Cardiac disease in myotonic dystrophy. Cardiovasc Res (1997) 1.98
George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. Obstet Gynecol (1971) 1.93
A new DNA marker tightly linked to the fragile X locus (FRAXA). Science (1989) 1.88
A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet (1989) 1.87
Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet (2008) 1.87
Huntington's chorea. The basis for long-term prevention. Lancet (1979) 1.87
Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet (1996) 1.83
Genetic linkage confirmed between the locus for myotonic dystrophy and the ABH-secretion and Lutheran blood group loci. Am J Hum Genet (1972) 1.82
Factors influencing age at onset and duration of survival in Huntington's chorea. Ann Hum Genet (1981) 1.79
Screening for Duchenne muscular dystrophy. Arch Dis Child (1989) 1.78
Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet (2007) 1.77
Localisation of the Becker muscular dystrophy gene on the short arm of the X chromosome by linkage to cloned DNA sequences. Hum Genet (1984) 1.74
Attitudes of mothers to neonatal screening for Duchenne muscular dystrophy. BMJ (1990) 1.72
Congenital myotonic dystrophy in Britain. II. Genetic basis. Arch Dis Child (1975) 1.71
Huntington disease: no evidence for locus heterogeneity. Genomics (1989) 1.70
Attitudes of subjects at risk and their relatives towards genetic counselling in Huntington's chorea. J Med Genet (1983) 1.67
A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms. J Med Genet (1982) 1.66
Decline in the predicted incidence of Huntington's chorea associated with systematic genetic counselling and family support. Lancet (1981) 1.64
Detection of linkage disequilibrium between the myotonic dystrophy locus and a new polymorphic DNA marker. Am J Hum Genet (1991) 1.64
Evidence from family studies that the gene causing Huntington disease is telomeric to D4S95 and D4S90. Am J Hum Genet (1989) 1.64
Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet (1999) 1.59
A genetic register for Huntington's chorea in South Wales. J Med Genet (1982) 1.56
Localization of a human Na+,K+-ATPase alpha subunit gene to chromosome 19q12----q13.2 and linkage to the myotonic dystrophy locus. Genomics (1988) 1.55
Absence of genetic heterogeneity in Duchenne muscular dystrophy shown by a linkage study using two cloned DNA sequences. J Med Genet (1983) 1.54
Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology (2002) 1.53
Becker muscular dystrophy: correlation of deletion type with clinical severity. J Med Genet (1990) 1.50
Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J Immunol (1997) 1.49
Dentatorubral and pallidoluysian atrophy (DRPLA). Clinical and neuropathological findings in genetically confirmed North American and European pedigrees. Mov Disord (1997) 1.49
Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch Dis Child (1982) 1.46
Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet (1999) 1.45
Congenital dystrophia myotonica. Neurology (1973) 1.45
Possible underascertainment of variant Creutzfeldt-Jakob disease: a systematic study. J Neurol Neurosurg Psychiatry (2002) 1.44
Genetic testing for familial hypertrophic cardiomyopathy in newborn infants. BMJ (1995) 1.44
Carrier detection in Duchenne muscular dystrophy. Evidence from a study of obligatory carriers and mothers of isolated cases. Arch Dis Child (1979) 1.43
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer (2004) 1.43
Genetic counselling in facioscapulohumeral muscular dystrophy. J Med Genet (1991) 1.42
Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol (1997) 1.41
Sanfilippo A disease in the fetus. J Med Genet (1974) 1.40
Marfan syndrome: exclusion of genetic linkage to the COL1A2 gene. Clin Genet (1986) 1.40
Estimation of age dependent penetrance in facioscapulohumeral muscular dystrophy by minimising ascertainment bias. J Med Genet (1989) 1.39
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer (2012) 1.39
Selection for presymptomatic testing for Huntington's disease: who decides? J Med Genet (1996) 1.39
Recurrence risk in osteogenesis imperfecta congenita. Lancet (1980) 1.38
A genetic marker for Huntington's chorea. Br Med J (Clin Res Ed) (1983) 1.38
Genetic prediction and family structure in Huntington's chorea. Br Med J (Clin Res Ed) (1985) 1.38
Genetic linkage relationships of seven DNA probes with Duchenne and Becker muscular dystrophy. Hum Genet (1985) 1.33
Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol (1999) 1.32
The apolipoprotein CII gene: subchromosomal localisation and linkage to the myotonic dystrophy locus. Hum Genet (1985) 1.31
X-linked hypohidrotic ectodermal dysplasia: DNA probe linkage analysis and gene localization. Hum Genet (1987) 1.31
Early diagnosis and secondary prevention of Duchenne muscular dystrophy. Arch Dis Child (1989) 1.30
Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet (2005) 1.29
Mapping genetic markers on human chromosome 19 using subchromosomal fragments in somatic cell hybrids. Cytogenet Cell Genet (1986) 1.29
Cerebellar haemangioblastoma and von Hippel-Lindau disease. Brain (1986) 1.29
Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol (2000) 1.27
Linkage analysis of peripheral neurofibromatosis (Von Recklinghausen disease) and chromosome 19 markers linked to myotonic dystrophy. J Med Genet (1986) 1.26
Genetic linkage between Huntington's disease and the DNA polymorphism G8 in South Wales families. J Med Genet (1985) 1.25
Duchenne muscular dystrophy in Wales: a 15 year study, 1971 to 1986. J Med Genet (1989) 1.24
Implications of diagnostic delay in Duchenne muscular dystrophy. Br Med J (Clin Res Ed) (1983) 1.23
Huntington's disease predictive testing: the case for an assessment approach to requests from adolescents. J Med Genet (1996) 1.23
Hereditary distal spinal muscular atrophy with vocal cord paralysis. J Neurol Neurosurg Psychiatry (1980) 1.23
The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Arch Dis Child (1993) 1.22
The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol (1998) 1.22
X-linked hypohidrotic ectodermal dysplasia: localization within the region Xq11-21.1 by linkage analysis and implications for carrier detection and prenatal diagnosis. Am J Hum Genet (1988) 1.21
Localisation of genetic markers and orientation of the linkage group on chromosome 19. Hum Genet (1984) 1.21
Anal abnormalities in childhood myotonic dystrophy--a possible source of confusion in child sexual abuse. Arch Dis Child (1992) 1.21